Your browser doesn't support javascript.
loading
Bisphosphonates in patients with renal cell carcinoma and bone metastases: a sunitinib global expanded-access trial subanalysis.
Vrdoljak, Eduard; Gore, Martin; Leyman, Sophie; Szczylik, Cezary; Kharkevich, Galina; Schöffski, Patrick; Torday, Laszlo; Mardiak, Josef; Zhang, Ke; Sajben, Peter; Sella, Avishay.
Afiliação
  • Vrdoljak E; Centre of Oncology, Medical School Split, University Hospital Split, Split, Spinciceva 1, 21000 Split, Croatia.
  • Gore M; Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK.
  • Leyman S; Pfizer, Boulevard de la Plaine 17, 1050 Elsene/Ixelles (Brussels), Belgium.
  • Szczylik C; Department of Oncology, Central Clinical Hospital, Military Institute of Medicine, Szaserόw 128, 00-909 Warsaw, Poland.
  • Kharkevich G; Biotherapy Department, N. N. Blokhin Russian Cancer Research Centre, 24 Kashirskoe Shosse, Moscow 115478, Russia.
  • Schöffski P; University Hospitals Leuven, Leuven Cancer Institute, Herestraat 49, 3000 Leuven, Belgium.
  • Torday L; Department of Oncotherapy, University of Szeged, Korányi fasor 12, 6720, Szeged, Hungary.
  • Mardiak J; Department of Medical Oncology, National Cancer Institute, Vlárska 7, 833 91 Bratislava, Slovakia.
  • Zhang K; Pfizer, 10646 Science Center Drive, La Jolla, San Diego, CA 92121, USA.
  • Sajben P; Pfizer, 235 East 42nd Street, New York, NY 10017, USA.
  • Sella A; Department of Oncology, Assaf Harofeh Medical Center Zerifin, Beer Yacov, Tel Aviv 70300, Israel.
Future Oncol ; 11(20): 2831-40, 2015.
Article em En | MEDLINE | ID: mdl-26118456
ABSTRACT

AIM:

To investigate retrospectively the effects of bone metastases and bisphosphonates in sunitinib-treated metastatic renal cell carcinoma patients. PATIENTS &

METHODS:

Patients in Groups (Gp) 1 and 2, but not Gp3, had bone metastases. Gp2 received bisphosphonates following standard practice.

RESULTS:

Gp2 had less favorable prognosis than Gp1. Gp3 had fewer metastases and the best prognosis. More serious adverse events occurred in Gp2 versus Gp1. The difference in overall survival between Gp1 and Gp2 was not significant after adjusting for covariates. Significantly shorter overall survival in Gp1 versus Gp3 persisted after adjusting for covariates.

CONCLUSION:

Bone metastases may have a negative prognostic impact in metastatic renal cell carcinoma. Bisphosphonates may have delayed early disease progression for prognostically worse sunitinib/bisphosphonate-treated patients.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Carcinoma de Células Renais / Conservadores da Densidade Óssea / Neoplasias Renais Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Ósseas / Carcinoma de Células Renais / Conservadores da Densidade Óssea / Neoplasias Renais Tipo de estudo: Clinical_trials Limite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2015 Tipo de documento: Article